Abstract: Compositions and methods relating to WSX-1 and p28 (IL-30) are provided. In particular, methods of treating inflammatory conditions in mammalian subjects using various WSX-1, p28, EBI3, and gp130 polypeptides and complexes or moieties that bind to or modulate activity of such complexes are described. Isolated or recombinant complexes including soluble WSX-1 or gp130 polypeptides, isolated or recombinant WSX-1 fusion proteins, and isolated or recombinant p28 fusion proteins are also described.

Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus filovirus immunogen including a consensus Marburgvirus filovirus glycoprotein MARV GP immunogen, a consensus Ebolavirus Sudan filovirus glycoprotein SEBOV GP immunogen and a consensus Ebolavirus Zaire glycoprotein ZEBOV GP immunogen are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Immunomodulatory methods and methods of inducing an immune response against filovirus, particularly Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire are disclosed. Method of preventing filovirus infection, particularly infection by Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire and methods of treating individuals infected with filovirus infection, particularly infection by Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire are disclosed. Consensus filovirus proteins are disclosed.

Abstract: The present invention relates to the discovery that the expression levels of some microRNAs (miRNAs) can use a diagnostic signature to predict transplant outcomes in a transplant recipient. Thus, in various embodiments described herein, the methods of the invention relate to methods of diagnosing a transplant subject for acute rejection such as acute cellular rejection (ACR), methods of predicting a subject's risk of having or developing ACR and methods of assessing in a subject the likelihood of a successful or failure minimization of immunosuppression therapy (IST) dosage from standard ranges.

Abstract: The invention includes compositions, methods and kits for the in vivo identification of an enzyme that binds to a substrate. The invention comprises, in part, a photoreactive moiety to aid in identification of such an enzyme.

Abstract: Proviral plasmids contain a modular gene expression cassette with one or a combination of (i) a wildtype 5? AAV2 ITR sequence flanked by unique restriction sites that permit ready removal or replacement of said ITR; (ii) a promoter flanked by unique restriction sites that permit ready removal or replacement of the entire promoter sequence; (iii) a polylinker sequence that permits insertion of a gene coding sequence without modification thereof, wherein the gene is operatively linked to, and under the regulatory control of, the aforementioned promoter; (iv) a bovine growth hormone polyadenylation sequence flanked by unique restriction sites that permit ready removal or replacement of said polyA sequence; and (v) a wildtype 3? AAV2 ITR sequence flanked by unique restriction sites that permit ready removal or replacement of the 3? ITR. These plasmids enable rapid manipulation of the components of the cassette, e.g.

Abstract: Provided herein are nucleic acid sequences encoding hepatitis B virus (HBV) core proteins, surface antigen proteins, fragments and combinations thereof as well as genetic constructs/vectors and vaccines that express said protein sequences. These vaccines are able to induce an immune response peripherally and in the liver by recruiting both cellular and humoral agents. Also provided are methods for prophylactically and/or therapeutically immunizing individuals against HBV. The combination vaccine can also be used for particular design vaccines for particular levels of immune responses to HBV challenge.

Abstract: The present disclosure generally relates to vaccine compositions for Herpes Simplex Viruses (HSV) types 1 and/or 2. The vaccines comprise isolated antigens or glycoprotein subunits of the viruses, optionally with an adjuvant, such as a cationic liposome DNA complex (CLDC). Also the present disclosure contains methods of vaccinating a subject utilizing these compositions.

Abstract: Provided is a durable oxygen sensitive probe of sufficient strength to withstand direct tissue pressures in vivo, the probe comprising a sensor chamber within a biocompatible, gas-permeable membrane containing an oxygen sensitive analyte solution producing oxygen quenchable phosphorescence when excited. Further provided is a tissue oxygen detection and measurement system comprising the probe, and methods for use of the probe and the system to directly, rapidly and accurately measure tissue oxygen levels in a patient without reliance on blood vessels or fluid protection of the probe.

Abstract: A spin locked balanced steady-state free precession (slSSFP) pulse sequence combines a balanced gradient echo acquisition with an off-resonance spin lock pulse for fast MRI. The transient and steady-state magnetization trajectory is solved numerically using the Bloch equations and is shown to be similar to balanced steady-state free precession (bSSFP) for a range of T2/T1 and flip angles, although the slSSFP steady-state could be maintained with considerably lower RF power. In both simulations and brain scans performed at 7 T, slSSFP is shown to exhibit similar contrast and SNR efficiency to bSSFP, but with significantly lower power.

Abstract: The inventive subject matter relates to novel synthetic processes which use a multifunctional compound (the “TERMINI compound”) having a masked or protected functional group, wherein the TERMINI compound is capable of quantitatively and irreversibly interrupting a living polymerization or a chain organic reaction. After deprotection or demasking of the functional group of the TERMINI compound, the same living polymerization or organic reaction resumes with 100% efficiency, or a different living polymerization or organic reaction resumes with 100% chemoselectivity, respectively. Once incorporated into a growing molecule, the TERMINI compound generates a branching point upon resumption of the polymerization or reaction.

Abstract: An optical fingerprinting method extracts high quality latent fingerprints from a surface without any invasive chemical or physical contact with the examined object, and requires no cooperation of the subject. Rather than employing extraneous material, the optical properties of the latent fingerprint are used to generate one or more images with sufficient contrast to distinguish the latent fingerprint or some other deformation in the surface. The system includes a light source oriented to apply light at an angle of incidence to the surface at the position to be examined for the latent fingerprint or deformation, a camera oriented to receive light specularly and diffusely reflected from the surface and/or by the fingerprint or deformation on the surface, and a processor that performs the computation for digital contrast enhancement and/or reprojection of the recovered fingerprint image to a frontal view if necessary.

Abstract: An immunization regimen is provided which involves priming with an E1, E4-deleted adenovirus and boosting with an E1-deleted adenovirus. The second administered adenovirus has a capsid of a serotype which is not cross-reactive with the previously administered adenovirus. Each of the adenoviruses carries a heterologous expression cassette comprising a nucleic acid sequence encoding a product for inducing an immune response under the control of regulatory control sequences which direct expression of the product. The expression cassettes can have the same or different regulatory control sequences. Further, a product containing the adenoviruses necessary to perform the immunization regimen is provided.

Abstract: The present inventive subject matter relates to novel antibacterial compounds that are capable of inhibiting bacterial multiplication and killing living bacteria. The present inventive subject matter further relates to methods for treating Gram positive bacterial infections using the inventive compounds.

Abstract: Novel non-crystalline, porous bioactive glass and ceramic materials that permit the in vitro formation of bone tissue when exposed to a tissue culture medium and inoculated with cells are disclosed. The present invention also discloses methods of treating bioactive glass materials to control pH so that when the glass is exposed to a tissue culture medium and then inoculated with cells, bone tissue growth occurs in vitro. The glass material disclosed is preferably formed from SiO.sub.2, CaO, Na.sub.2 O and P.sub.2 O.sub.5 and the porous, non-crystalline structure is most preferably created by melting the constituents, cooling and pulverizing the resulting glass, and then forming and hot pressing the powder. The glass of the present invention may be formed to produce templates that are useful for various indications, as well as granules that may be formed into a paste.

Abstract: The present invention relates to the synthesis of functional human hemoglobin and other proteins in erythroid tissues of transgenic non-human animals and erythroid cell lines. It is based on the discovery that two of the five hypersensitivity sites of the .beta.-globin locus are sufficient to result in high level expression of human .alpha.- or .beta.-globin transgenes. The present invention also provides for novel recombinant nucleic acid vectors which may be used to produce .alpha.-globin as well as other proteins of interest in quantity in the red blood cells of transgenic animals or cell cultures of erythroid lineage. The vectors of the invention comprise at least one of the major DNase I hypersensitivity sites associated with the .beta.-globin locus together with a gene of interest. In a specific embodiment of the invention, a vector which comprises two DNase I hypersensitivity sites together with the human .alpha.-globin gene is used to create transgenic animals which produce human .alpha.